Watson Pharmaceuticals (Actavis Inc.) / Schein Pharmaceutical Inc.

Multi-Source Generics (Multiple Indications)

Disease Overview

Multi-source generics span every major therapeutic area — cardiovascular, CNS, anti-infectives, women's health, pain — once branded products lose patent protection. Generic firms compete on manufacturing scale, ANDA pipeline depth, supply reliability, and pricing rather than on disease biology.

Competitive Landscape

By 2000 the US generics industry was consolidating rapidly around five scaled players: Teva (post-Novopharm), Mylan, Watson, Schein, and Ivax, with Sandoz/Geneva, Barr, and Andrx in the next tier. Watson had built its franchise on niche off-patent and women's-health generics plus a small branded book; Schein brought an oral-solid-dose generic catalog of nearly 100 products and Marsam/Steris injectables, doubling Watson's revenue base to ~$1.2B and lifting it into the top tier of US generics manufacturers. The deal mattered because Bayer Corp. and the Schein family controlled 74% of Schein and tendered into the $19.50/share cash leg, giving Watson rapid scale at a moment when Hatch-Waxman first-to-file Paragraph IV economics were becoming the primary value driver in generics. The combination broadened Watson's ANDA filing pipeline, added injectable manufacturing capacity, and positioned it to absorb the next wave of patent expirations. The transaction's $674M total value (cash tender plus stock-merger second step) was modest by later standards but set the consolidation template that Teva, Mylan, and Actavis (the eventual Watson successor) would follow throughout the 2000s. Source: https://www.thepharmaletter.com/article/watson-to-acquire-schein-pharmaceutical-in-deal-worth-674-million